IBD: Microbiota manipulation through diet and modified bacteria

Digestive Diseases

Volumn 32, Issue , 2014, Pages 18-25

  Simpson, Hannah L ^a   Campbell, Barry J ^a   Rhodes, Jonathan M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Contrabiotics; Crohn's disease; Fibre; Microbiota; Mucosal barrier; Prebiotics; Ulcerative colitis

Indexed keywords

PHOSPHATIDYLCHOLINE; PREBIOTIC AGENT; VITAMIN D;

COLON MUCOSA; CONFERENCE PAPER; CROHN DISEASE; DIET SUPPLEMENTATION; ESCHERICHIA COLI; FECES MICROFLORA; FUSOBACTERIUM; GENOTYPE ENVIRONMENT INTERACTION; HAEMOPHILUS; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; LACTIC ACID BACTERIUM; MUCOSAL IMMUNITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SALMONELLA; SHIGELLA; ULCERATIVE COLITIS; VEILLONELLA; BACTERIUM; DIET; DIET THERAPY; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; METABOLISM; MICROBIOLOGY; MICROFLORA;

BACTERIA; DIET; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; PREBIOTICS; VITAMIN D;

EID: 84919785262     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000367821     Document Type: Conference Paper

References (59)

1. Jostins L, Ripke S, Weersma RK, et al: Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
2. Fiocchi C: Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand Dig Dis 2009; 27: 226-235.
3. Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO: Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014, Epub ahead of print.
4. Fujimura Y, Kamoi R, Iida M: Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut 1996; 38: 724-732.
5. VanDussen KL, Liu TC, Li D, Towfic F, Modiano N, Winter R, Haritunians T, Taylor KD, Dhall D, Targan SR, Xavier RJ, McGovern DP, Stappenbeck TS: Genetic variants synthesize to produce Paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 2014; 146: 200-209.
6. Johansson MEV, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia LJ, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjovall H, Hansson GC: Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014; 63: 281-291.
7. Zhang YZ, Li YY: Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-99.
8. Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis 2011; 17: 831-848.
9. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ: Ulcerative colitis. Lancet 2012; 380: 1606-1619.
10. Qin J, Li R, Raes J, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
11. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I: Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years World J Gastroenterol 2014; 20: 1192-1210.
12. Morgan XC, Tickle TL, Sokol H, et al: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13:R79.
13. Tong M, Li X, Wegener Parfrey L, Roth B, Ippoliti A, Wei B, Borneman J, McGovern DP, Frank DN, Li E, Horvath S, Knight R, Braun J: A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One 2013; 8:e80702.
14. Nagalingam NA, Kao JY, Young VB: Microbial ecology of the murine gut associated with the development of dextran sodium sulfateinduced colitis. Inflamm Bowel Dis 2011; 17: 917-926.
15. Gevers D, Kugathasan S, Denson Lee A, et al: The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-392.
16. Smith EJ, Thompson AP, O'Driscoll A, Clarke DJ: Pathogenesis of adherent-invasive Escherichia coli. Future Microbiol 2013; 8: 1289-300.
17. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
18. Krauss E, Agaimy A, Neumann H, Schulz U, Kessler H, Hartmann A, Neurath MF, Raithel M, Mudter J: Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy. Int J Clin Exp Pathol 2012; 5: 411-421.
19. Van Kruiningen HJ, Ganley LM, Freda BJ: The role of Peyer's patches in the age-related incidence of Crohn's disease. J Clin Gastroenterol 1997; 25: 470-475.
20. Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, Buttner T, Porstmann T, Porstmann S, Liedvogel B, Bogdanos DP, Laass MW, Conrad K: Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta 2011; 412: 718-724.
21. Schulz O, Pabst O: Antigen sampling in the small intestine. Trends Immunol 2013; 34: 155-161.
22. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF: Immunocytochemical evidence of Listeria, Escherichia coli , and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-1404.
23. Ryan P, Kelly RG, Lee G, Collins JK, O'Sullivan GC, O'Connell J, Shanahan F: Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. Am J Gastroenterol 2004; 99: 1539-1543.
24. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A: Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529-5537.
25. Sokol H, Pigneur B, Watterlot L, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
26. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633.
27. Scaldaferri F, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Boskoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A: Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013; 2013: 435268.
28. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO: Randomised, doubleblind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923-929.
29. Kanauchi O, Suga T, Tochihara M, et al: Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002; 37(suppl 14):67-72.
30. Bamba T, Kanauchi O, Andoh A, Fujiyama Y: A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002; 17: 818-824.
31. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG: Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an heal pouch-anal anastomosis. Dis Colon Rectum 2002; 45: 621-627.
32. Kanauchi O, Andoh A, Mitsuyama K: Effects of the modulation of microbiota on the gastrointestinal immune system and bowel function. J Agric Food Chem 2013; 61: 9977-9983.
33. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999; 94: 427-433.
34. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM: Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004; 127: 80-93.
35. Roberts CL, Keita AV, Duncan SH, O'Kennedy N, Soderholm JD, Rhodes JM, Campbell BJ: Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010; 59: 1331-1339.
36. Roberts CL, Keita AV, Parsons BN, Prorok-Hamon M, Knight P, Winstanley C, O'Kennedy N, Soderholm JD, Rhodes JM, Campbell BJ: Soluble plantain fibre blocks adhesion and M-cell translocation of intestinal pathogens. J Nutr Biochem 2013; 24: 97-103.
37. Parsons BN, Wigley P, Simpson HL, et al: Dietary supplementation with soluble plantain non-starch polysaccharides inhibits intestinal invasion of Salmonella typhimurium in the chicken. PLoS One 2014; 9:e87658.
38. Ananthakrishnan AN: Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep 2013; 15: 302.
39. Backman RV: The effects of plantain nonstarch polysaccharide upon the gut bacteria; doctoral thesis, University of Aberdeen, 2009. http://digitool.abdn.ac.uk:80/webclient/Deli veryManagerapplication=DIGITOOL-3&owner=resourcediscovery&custom-att-2=simple-viewer&pid=131552.
40. Bermudez-Humaran LG, Aubry C, Motta JP, Deraison C, Steidler L, Vergnolle N, Chatel JM, Langella P: Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 2013; 16: 278-283.
41. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B, Bowel II: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000; 119: 1473-1482.
42. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-1355.
43. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L: A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-759.
44. Motta JP, Magne L, Descamps D, et al: Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011; 140: 1272-1282.
45. Torres MI, Rios A: Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 2008; 14: 1972-1980.
46. Torres J, Danese S, Colombel JF: New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 2013; 62: 1642-1652.
47. Stremmel W, Ehehalt R, Autschbach F, Karner M: Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 147: 603-610.
48. Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W: First multicenter study of modified release phosphatidylcholine 'LT-02' in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014; 109: 1041-1051.
49. Roberts CL, Rushworth SL, Richman E, Rhodes JM: Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. J Crohns Colitis 2013; 7: 338-341.
50. Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF: Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis 2013; 7:e407-e413.
51. Jorgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Kelsen J, Christensen LA, Dahlerup JF: Clinical trial: vitamin D 3 treatment in Crohn's disease-A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-383.
52. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK: Vitamin D 3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-243.
53. Flanagan PK, Campbell, BJ, Rhodes JM: Vitamin D enhanced macrophage function and improves killing of Crohn's associated E. coli. J Crohns Colitis 2013; 7:S20.
54. Kanauchi O, Mitsuyama K, Homma T, et al: Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 2003; 12: 701-704.
55. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, Araki Y, Fujiyama Y, Toyonaga A, Sata M, Kojima A, Fukuda M, Bamba T: Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13: 643-647.
56. Hafer A, Kramer S, Duncker S, Kruger M, Manns MP, Bischoff SC: Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol 2007; 7: 36.
57. De Preter V, Joossens M, Ballet V, Shkedy Z, Rutgeerts P, Vermeire S, Verbeke PK: Metabolic profiling of the impact of oligofructoseenriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial. Clin Trans Gastroenterol 2013; 4:e30.
58. Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S: Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a doubleblinded randomised controlled trial. Gut 2012; 61: 958.
59. Hallert C, Kaldma M, Petersson BG: Ispaghula husk may relieve gastrointestinal symptoms in ulcerative-colitis in remission. Scand J Gastroenterol 1991; 26: 747-750.